London, UK – [Insert Date] – In a significant development for the fight against seasonal influenza, pharmaceutical giant GSK has announced promising progress for its investigational mRNA-based flu vaccine. The candidate has successfully navigated a mid-stage trial, demonstrating superior immune responses compared to existing market standards, and is now poised to enter Phase III studies. This advancement comes less than a month after Moderna secured landmark FDA approval for its own mRNA-based seasonal flu vaccine, mFlusvia, signaling a potential new era in influenza prevention and intensifying the competition in this crucial public health sector.
GSK’s move to advance its mRNA vaccine candidate to late-stage clinical trials is based on the compelling results of the Flu-028 study (NCT07204964). Presented at the prestigious OPTIONS XIII Conference for the Control of Influenza in Washington D.C., the data indicated that participants receiving GSK’s multivalent jab elicited higher immune responses than those administered comparator standard and high-dose flu vaccines. Crucially, the experimental vaccine also maintained an "acceptable" safety profile and demonstrated a manageable short-term inflammatory response, according to GSK’s own assessment. This dual achievement of enhanced efficacy and a favorable safety profile positions GSK’s candidate as a formidable contender in the evolving influenza vaccine market.
The Road to Phase III: A Chronological Overview of GSK’s mRNA Vaccine Development
GSK’s journey with its mRNA-based influenza vaccine has been marked by strategic progression and a focus on scientific validation. The decision to proceed to Phase III is the culmination of meticulous research and development, building upon a foundation of promising preclinical and early-stage clinical data.
The pivotal Flu-028 study, conducted as a Phase IIa trial, played a crucial role in this advancement. This study involved the randomization of 971 adult volunteers, who were administered varying dose levels and formulations of GSK’s experimental vaccine or chosen marketed comparator vaccines, including both standard-dose and high-dose options. The trial meticulously accounted for age-related differences in immune responses, with participants stratified into younger (18-64 years) and older (65-plus years) age categories, allowing for a nuanced evaluation of the vaccine’s performance across different demographic groups.
The positive efficacy outcomes observed in the Flu-028 study, coupled with the identification of an optimized vaccine configuration, have paved the way for the next critical phase. GSK will now advance an optimized B-strain haemagglutinin (HA) form of its mRNA vaccine into Phase III clinical trials. The company has expressed its ambition to initiate these pivotal trials in September 2026, a timeline that strategically places it in close proximity to the market entry of its key competitor, Moderna’s mFlusvia.
Pioneering a New Generation of Influenza Vaccines: The Science Behind GSK’s Approach
GSK’s investigational mRNA vaccine is not merely an incremental improvement; it represents a significant leap forward in vaccine design by targeting two critical surface proteins of the influenza virus: haemagglutinin (HA) and neuraminidase (NA). This dual-targeting strategy is a key differentiator and a core element of GSK’s ambition to provide enhanced protection against the complexities of seasonal flu.
According to Dr. Sanjay Gurunathan, GSK’s Head of Vaccines and Infectious Disease R&D, the ability to target both HA and NA could significantly bolster protection. "This approach has the potential to better protect people from flu," Dr. Gurunathan stated, emphasizing the critical roles these proteins play in the virus’s ability to infect host cells. Haemagglutinin is essential for the virus to bind to and enter respiratory cells, while neuraminidase is crucial for the release of newly formed virus particles from infected cells, enabling further spread. By eliciting an immune response against both proteins, GSK’s vaccine aims to create a more robust and comprehensive defense against a wider spectrum of flu strains and potentially reduce the severity of infection.
Upon the commencement of its Phase III trial, GSK’s mRNA vaccine will hold the distinction of being the first to evaluate an mRNA-based flu vaccine targeting both HA and NA in late-stage clinical evaluation. This pioneering effort underscores GSK’s commitment to harnessing cutting-edge technology to address persistent public health challenges.
Supporting Data: Quantifying the Immune Response and Safety Profile
The positive trajectory of GSK’s mRNA flu vaccine is firmly anchored in the quantifiable data emerging from the Flu-028 study. While specific numerical data on antibody titers and immune response metrics are typically detailed in scientific publications and conference presentations, the reported outcomes provide a clear indication of its superior performance.
The study demonstrated that recipients of GSK’s multivalent mRNA jab experienced "higher immune responses" when compared to those who received marketed comparator standard and high-dose flu shots. This suggests a more potent and potentially longer-lasting immune activation. In the context of influenza vaccines, higher immune responses often correlate with greater efficacy in preventing infection and reducing the severity of illness.
Furthermore, the "acceptable" safety and short-term inflammatory response profile is a critical component of the trial’s success. Vaccine safety is paramount, and any investigational vaccine must undergo rigorous scrutiny to ensure it is well-tolerated by the population. An acceptable safety profile, coupled with manageable inflammatory responses, indicates that the vaccine is likely to be suitable for widespread use. This is particularly important for a seasonal vaccine administered annually to large populations.
The trial’s design, which involved stratifying participants by age, is also a crucial aspect of the supporting data. Influenza disproportionately affects certain age groups, with older adults often experiencing more severe outcomes. Demonstrating comparable or superior efficacy and safety across different age brackets is essential for a successful public health intervention. The reported success in this regard suggests GSK’s vaccine could offer broad protection.
The Evolving Competitive Landscape: Moderna’s mFlusvia and Market Projections
GSK’s advancement into Phase III occurs at a pivotal moment, with Moderna having recently secured FDA approval for its mRNA-based seasonal flu vaccine, mFlusvia. This development has not only validated the mRNA platform for seasonal influenza but also established Moderna as an early market leader.
Moderna’s mFlusvia achieved regulatory approval in August 2026, following a regulatory pathway that was not without its challenges. The vaccine initially faced a refusal from the FDA to review it, a hurdle that was eventually overcome. This underscores the rigorous evaluation process that new vaccines undergo, and Moderna’s success highlights the increasing acceptance and efficacy of mRNA technology in infectious disease prevention.
The entry of two mRNA-based flu vaccines into the market is poised to reshape the influenza prevention landscape. Historically, the seasonal flu vaccine market has been dominated by traditional inactivated or recombinant protein-based vaccines. The introduction of mRNA technology offers the potential for faster development cycles, improved manufacturing scalability, and potentially enhanced immunogenicity, as demonstrated by the early results from both GSK and Moderna.
According to sales and consensus forecasts from GlobalData, the parent company of Clinical Trials Arena, Moderna’s mFlusvia is projected to generate significant revenue, with an estimated $831 million in sales by 2032. This forecast highlights the substantial market potential for effective and innovative flu vaccines. GSK’s progress suggests that it aims to capture a significant share of this growing market, offering an alternative and potentially superior mRNA-based option.
Is mRNA Back in the Limelight? Navigating Political Scrutiny and Scientific Promise
The recent strides made by GSK and Moderna in the mRNA vaccine space arrive at a complex juncture for the mRNA modality itself. While mRNA technology was thrust into the global spotlight by its revolutionary role in combating the COVID-19 pandemic, it has also faced significant political headwinds, particularly in the United States.
Concerns regarding the safety and long-term implications of mRNA vaccines have been voiced by influential political figures, including former US Health Secretary Robert F. Kennedy Jr. (RFK Jr.). His public skepticism and actions, such as the cessation of government funding for 22 mRNA vaccine development initiatives worth $500 million in August 2025, created an environment of uncertainty. This political storm contributed to a significant decline in private equity financing for mRNA-focused ventures, with funding reportedly dropping by 82% in 2025 compared to 2023.
However, the landscape is not solely defined by political challenges. The scientific promise of mRNA technology continues to be a driving force for innovation. A recent landmark Phase III success for Moderna’s mRNA-based cancer vaccine, intismeran autogene, in treating melanoma has reignited analyst interest. This success, particularly its potential to offer additive efficacy in the adjuvant setting when combined with standard treatments like Keytruda (pembrolizumab), suggests that mRNA technology’s applications extend far beyond infectious diseases.
Despite this renewed scientific optimism, some analysts caution against an immediate and wholesale return of investor capital to mRNA-based therapies. Andrew Tsai, a senior equity research analyst at Jefferies, previously noted that investors are likely to adopt a more measured approach. Their long-term commitment, he suggested, will likely be contingent on the demonstrated success of mRNA-based drug candidates across a broader spectrum of solid tumor types.
In this context, the successful progression of GSK’s mRNA flu vaccine, alongside Moderna’s approved product, represents a crucial validation of the mRNA platform for infectious disease prevention. It demonstrates that, despite political scrutiny and market fluctuations, the underlying scientific potential of mRNA technology continues to yield tangible advancements that could profoundly impact public health. The success of these seasonal flu vaccines could serve as a powerful testament to the modality’s capabilities, potentially influencing investor confidence and further research into its diverse applications.
About the Author
